Novo Nordisk has a two-tier management structure consisting of the Board of Directors and Executive Management. The Board of Directors supervises the performance of the company, its management and organisation on behalf of the shareholders. It also participates in determining the company strategy. Executive Management, in turn, has responsibility for the company's daily operations. The two bodies are separate, and no person serves as a member of both.
The Board appoints members of Executive Management and determines its remuneration.
The Chairmanship reviews the performance of the executives. As part
of the Organisational Development Process, the Chairmanship identifies
successors to executives and presents the names of such candidates to
the Board for approval.
The Executive Management has established a number of executive committees to assist or implement Executive Management's decisions. Such committees include the Research Portfolio Committee responsible for management of the research portfolio and the early device portfolio, the Product Development Committee responsible for management of the product development and device portfolios and the Disclosure Committee overseeing Novo Nordisk’s disclosures to the capital markets.